Novartis Presents New Two-year Data for Cosentyx Showing No Progression in Joint Damage in 84% of Psoriatic Arthritis Patients
November 07, 2015 at 20:03 PM EST
Novartis (NYSE: NVS) announced today new results for Cosentyx® (secukinumab) showing no further progression in joint damage in 84% of ...